共 155 条
[1]
Siegel RL(2017)Cancer Statistics CA Cancer J Clin 67 7-30
[2]
Miller KD(2012)Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis Cancer Res 72 4383-4393
[3]
Jemal A(2012)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Lancet 376 687-697
[4]
Dulak AM(2012)HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients Sci World J 2012 941259-1393
[5]
Schumacher SE(2007)Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction Hum Pathol 38 1386-267
[6]
van Lieshout J(2013)Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment Gastric Cancer 16 261-40
[7]
Imamura Y(2014)A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond Cancer Lett 351 30-488
[8]
Fox C(2016)Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial BMC Cancer 16 68-1168
[9]
Shim B(2015)Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer Eur J Cancer 51 482-184
[10]
Bang YJ(2014)Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1) Br J Cancer 110 1163-757